Ralf Dieter Hofheinz

Summary

Publications

  1. doi An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors
    Ralf Dieter Hofheinz
    Universitatsmedizin Mannheim, Heidelberg University, Mannheim, Germany
    Clin Cancer Res 16:4666-74. 2010
  2. doi Population-based patterns of care in the first-line treatment of patients with advanced esophagogastric adenocarcinoma in Germany
    Ralf Dieter Hofheinz
    TagesTherapieZentrum am Interdisziplinären Tumorzentrum Mannheim und III Medizinische Klinik, Universitatsmedizin Mannheim, Germany
    Onkologie 33:512-8. 2010
  3. pmc Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma
    Martina Mayr
    Department of Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    BMC Cancer 12:587. 2012
  4. pmc Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
    Josef Thaler
    Department of Internal Medicine IV Haematology and Oncology, Hospital Wels Grieskirchen, Wels, Austria
    BMC Cancer 12:438. 2012
  5. pmc Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer
    R D Hofheinz
    TagesTherapieZentrum TTZ, Interdisciplinary Tumour Centre, University Hospital Mannheim, University of Heidelberg, Theodor Kutzer Ufer 1 3, Haus 9, Mannheim 68167, Germany
    Br J Cancer 107:1678-83. 2012
  6. doi Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial
    Ralf Dieter Hofheinz
    University Hospital Mannheim, University of Heidelberg, Mannheim, Germany
    Lancet Oncol 13:579-88. 2012
  7. ncbi Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer
    Ralf Dieter Hofheinz
    Onkologisches Zentrum, III, Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Int J Radiat Oncol Biol Phys 66:1384-90. 2006
  8. pmc Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy
    Juliana Schwaab
    III, Medizinische Klinik, Universitatsmedizin Mannheim, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    BMC Cancer 11:363. 2011
  9. doi KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer
    Philipp Erben
    III Medizinische Klinik, Universitatsmedizin Mannheim, Universitat Heidelberg, Mannheim, Germany
    Int J Radiat Oncol Biol Phys 81:1032-8. 2011
  10. ncbi Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study
    Ralf Dieter Hofheinz
    Onkologisches Zentrum, III Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Anticancer Drugs 16:39-45. 2005

Collaborators

Detail Information

Publications36

  1. doi An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors
    Ralf Dieter Hofheinz
    Universitatsmedizin Mannheim, Heidelberg University, Mannheim, Germany
    Clin Cancer Res 16:4666-74. 2010
    ..Secondary objectives included evaluation of safety, efficacy, and pharmacokinetics...
  2. doi Population-based patterns of care in the first-line treatment of patients with advanced esophagogastric adenocarcinoma in Germany
    Ralf Dieter Hofheinz
    TagesTherapieZentrum am Interdisziplinären Tumorzentrum Mannheim und III Medizinische Klinik, Universitatsmedizin Mannheim, Germany
    Onkologie 33:512-8. 2010
    ..We investigated temporal trends in therapy and factors influencing treatment decisions for these patients during a 4-year period...
  3. pmc Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma
    Martina Mayr
    Department of Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    BMC Cancer 12:587. 2012
    ..Targeted inhibition of platelet derived growth factor receptor (PDGFR) by imatinib may influence tumor growth and amplify chemotherapeutic effects...
  4. pmc Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
    Josef Thaler
    Department of Internal Medicine IV Haematology and Oncology, Hospital Wels Grieskirchen, Wels, Austria
    BMC Cancer 12:438. 2012
    ..Here we report additional descriptive tolerability and quality of life data from this trial...
  5. pmc Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer
    R D Hofheinz
    TagesTherapieZentrum TTZ, Interdisciplinary Tumour Centre, University Hospital Mannheim, University of Heidelberg, Theodor Kutzer Ufer 1 3, Haus 9, Mannheim 68167, Germany
    Br J Cancer 107:1678-83. 2012
    ..In the present analysis, we sought to evaluate the potential association of HFSR and survival in German patients with metastatic colorectal cancer and locally advanced rectal cancer treated with cape in clinical trials...
  6. doi Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial
    Ralf Dieter Hofheinz
    University Hospital Mannheim, University of Heidelberg, Mannheim, Germany
    Lancet Oncol 13:579-88. 2012
    ..Fluorouracil-based chemoradiotherapy is regarded as a standard perioperative treatment in locally advanced rectal cancer. We investigated the efficacy and safety of substituting fluorouracil with the oral prodrug capecitabine...
  7. ncbi Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer
    Ralf Dieter Hofheinz
    Onkologisches Zentrum, III, Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Int J Radiat Oncol Biol Phys 66:1384-90. 2006
    ..To establish the feasibility and efficacy of chemotherapy with capecitabine, weekly irinotecan, cetuximab, and pelvic radiotherapy for patients with locally advanced rectal cancer...
  8. pmc Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy
    Juliana Schwaab
    III, Medizinische Klinik, Universitatsmedizin Mannheim, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    BMC Cancer 11:363. 2011
    ..In search for potential prognostic molecular markers we investigated the expression of VEGFR-1, VEGFR-2 and TKTL1 in patients with LARC treated with neoadjuvant chemoradiotherapy and cetuximab...
  9. doi KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer
    Philipp Erben
    III Medizinische Klinik, Universitatsmedizin Mannheim, Universitat Heidelberg, Mannheim, Germany
    Int J Radiat Oncol Biol Phys 81:1032-8. 2011
    ..The predictive and prognostic value of the KRAS and BRAF point mutations as well as PTEN expression in patients with locally advanced rectal cancer (LARC) treated with cetuximab-based neoadjuvant chemoradiotherapy is unknown...
  10. ncbi Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study
    Ralf Dieter Hofheinz
    Onkologisches Zentrum, III Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Anticancer Drugs 16:39-45. 2005
    ..Efficacy and toxicity data are comparable to 5-FU/irinotecan combinations, although the likelihood of severe diarrhea appears to be higher with capecitabine/irinotecan...
  11. ncbi Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study
    Manuel Barreto Miranda
    III Medizinische Klinik, Hämatologie und Onkologie, Universitatsmedizin Mannheim, Mannheim, Germany
    J Cancer Res Clin Oncol 140:829-37. 2014
    ..We conducted a multicenter phase II study to assess the toxicity and efficacy of a combination of mitomycin C (MMC) and capecitabine in pretreated patients with metastatic or locally advanced gastric cancer...
  12. ncbi Characteristics, treatment and prognostic factors of patients with gynaecological malignancies treated in a palliative care unit at a university hospital
    Samantha Aeckerle
    III Medizinische Klinik, Hämatologie und Onkologie, Universitatsmedizin Mannheim, Universitat Heidelberg, Germany
    Onkologie 36:642-8. 2013
    ..Limited clinical data have been published on patients suffering from advanced gynaecological malignancies treated in palliative care units, and little is known about prognostic factors...
  13. ncbi Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial
    Senta Ulrike Gnad-Vogt
    Onkologisches Zentrum, III Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Anticancer Drugs 16:435-40. 2005
    ..Its safety and good tolerability as established in the phase I trial was confirmed...
  14. ncbi Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro
    Claudia Umbreit
    Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty of Mannheim, University of Heidelberg, Mannheim, Germany
    Anticancer Res 33:2457-65. 2013
    ....
  15. doi mRNA expression of platelet-derived growth factor receptor-beta and C-KIT: correlation with pathologic response to cetuximab-based chemoradiotherapy in patients with rectal cancer
    Philipp Erben
    III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Int J Radiat Oncol Biol Phys 72:1544-50. 2008
    ....
  16. doi Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status
    Nadine Lukan
    III Medizinische Klinik, Universitatsmedizin Mannheim, Mannheim, Deutschland
    Oncology 77:293-9. 2009
    ..Anal cancers universally express the epidermal growth factor receptor (EGFR) and KRAS mutations have not been reported in anal cancer thus far...
  17. ncbi Infusional 5-fluorouracil and mitomycin C: an effective regimen in the treatment of advanced gastric cancer
    Jochen Rudi
    Abteilung Innere Medizin I, Theresienkrankenhaus und St Hedwig Klinik GmbH, Mannheim, Germany
    Onkologie 28:128-32. 2005
    ..The present analysis was carried out to evaluate the safety and efficacy of 5-FU/FA in combination with 3-weekly mitomycin C (MMC) in patients with advanced gastric cancer...
  18. ncbi Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro
    Christoph Aderhold
    Department of Otorhinolaryngology Head and Neck Surgery, University Hospital Mannheim, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    Anticancer Res 33:1951-61. 2013
    ....
  19. doi Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma
    Jens Kruth
    III Medizinische Klinik, Hämatologie und Onkologie, Universitatsmedizin Mannheim, Ruprecht Karls Universitat Heidelberg, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    J Cancer Res Clin Oncol 136:1845-51. 2010
    ..Therefore, we have established a combination regimen of these drugs (DocMitoCape), which demonstrated preliminary activity especially in bile duct and pancreatic carcinoma...
  20. doi Cancer patients and advance directives: a survey of patients in a hematology and oncology outpatient clinic
    Elisabeth Hubert
    III Medizinische Klinik, Universitatsmedizin Mannheim, Universitat Heidelberg, Germany
    Onkologie 36:398-402. 2013
    ..3 years after the law passed, we surveyed patients with malignant diseases with regards to their views on advance directives...
  21. ncbi Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro
    Claudia Umbreit
    Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Mannheim, D 68167 Mannheim, Germany
    Oncol Rep 32:668-76. 2014
    ..Extended studies and clinical trials are needed to further investigate these findings in HPV-associated HNSCC. ..
  22. pmc Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases--clinical results
    Judit Boda-Heggemann
    Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany
    Radiat Oncol 7:92. 2012
    ..Outcome and toxicity were retrospectively evaluated in a single-institution patient cohort who had undergone ultrasound-guided breath-hold SABR...
  23. doi Metastatic esophagogastric adenocarcinoma: trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval
    Deniz Gencer
    TagesTherapieZentrum TTZ am Interdisziplinären Tumorzentrum Mannheim ITM and III Medizinische Klinik für Hämatologie und Onkologie, Universitatsmedizin Mannheim, Universitat Heidelberg, 68167 Mannheim, Germany
    J Cancer Res Clin Oncol 139:337-45. 2013
    ..Here, we sought to evaluate factors influencing treatment decisions with special focus on the implementation of HER2 testing during the first year after trastuzumab market approval in Germany...
  24. doi Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer
    Judit Boda-Heggemann
    Klinik fur Strahlentherapie und Radioonkologie, Universitatsmedizin Mannheim, Universitat Heidelberg, Mannheim, Germany
    Int J Radiat Oncol Biol Phys 75:1187-95. 2009
    ..conventional three-dimensional conformal radiotherapy (3D-CRT) and standard chemotherapy in these patients while maintaining or reducing renal toxicity...
  25. doi Alpha-fetoprotein expressing metastastic adenocarcinoma of the esophago-gastric junction responding favorably to capecitabine and oxaliplatin
    Melanie Kripp
    Onkologisches Zentrum, III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Anticancer Drugs 20:75-8. 2009
    ..He was treated with capecitabine and oxaliplatin-based combination therapy. A long-lasting major remission was observed resulting in a survival of 18.5 months...
  26. ncbi Expression of the mutated transketolase TKTL1, a molecular marker in gastric cancer
    Wilko I Staiger
    Department of Surgery, University Hospital Mannheim, 68135 Mannheim, Germany
    Oncol Rep 16:657-61. 2006
    ..Since molecular targeted inhibition of transketolase enzyme reactions suppresses tumor growth and metastasis, TKTL1 could be a relevant target for anti-transketolase therapies in gastric cancer...
  27. ncbi Quality of life and symptom evaluation in daily oncology practice: a survey of 150 patients with advanced gastrointestinal tumours receiving palliative chemotherapy
    Katharina Schultheis
    TagesTherapieZentrum, Interdisziplinäres Tumorzentrum, Mannheim, Mannheim, Germany
    Onkologie 36:33-7. 2013
    ..0) using assessment tools with an emphasis on pain and depression...
  28. ncbi Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient
    Ralf Dieter Hofheinz
    III Medical Clinic, University Hospital Mannheim, University of Heidelberg, Wiesbadener Strasse 7 11, 68167 Mannheim, Germany
    Cancer Chemother Pharmacol 53:276-7. 2004
    ..We report here a third patient with an immune-haematological finding favouring a bispecific mechanism (immune-complex and penicillin type) of oxaliplatin-induced haemolysis...
  29. ncbi Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer
    Karoline Horisberger
    Chirurgische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Anticancer Drugs 20:519-24. 2009
    ....
  30. doi Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Melanie Kripp
    III Medizinische Klinik, Universitatsmedizin Mannheim, Universitat Heidelberg, Theodor Kutzer Ufer 1 3, 68167, Mannheim, Germany
    Gastric Cancer 17:181-7. 2014
    ..Using validated instruments, we prospectively assessed QOL within the randomized FLOT65+ phase II trial...
  31. ncbi Liposomal encapsulated anti-cancer drugs
    Ralf Dieter Hofheinz
    Onkologisches Zentrum, III Medizinische Klinik, Fakultät für Klinische Medizin Mannheim, Universitat Heidelberg, Mannheim, Germany
    Anticancer Drugs 16:691-707. 2005
    ..Meanwhile, virtually all anti-cancer drugs have been encapsulated in liposomes using different technologies. This review will summarize preclinical and clinical data of approved and exemplary emerging liposomal anti-cancer agents...
  32. doi Molecular analysis of desmoid tumors with a high-density single-nucleotide polymorphism array identifies new molecular candidate lesions
    Philipp Erben
    III Medizinische Klinik, Sarkomzentrum, ITM Interdisziplinäres Tumorzentrum, Universitatsmedizin Mannheim, Ruprecht Karls Universitat Heidelberg, Mannheim, Germany
    Onkologie 35:684-9. 2012
    ..The mutation status of the gene coding for catenin (cadherin-associated protein) beta 1 (CTNNB1) and trisomy 8 on the chromosomal level have been described to have prognostic relevance...
  33. doi Preoperative staging of rectal tumors: comparison of endorectal ultrasound, hydro-CT, and high-resolution endorectal MRI
    Dietmar J Dinter
    Institut fur Klinische Radiologie und Nuklearmedizin, Universitatsklinikum Mannheim, Mannheim, Germany
    Onkologie 31:230-5. 2008
    ..The aim of this study was to compare transrectal ultra-sound (TRUS), hydro-computed tomography (hydro-CT), and endorectal magnetic resonance imaging (MRI) in the preoperative staging of rectal cancer...
  34. ncbi Presentation, treatment, and analysis of prognostic factors of terminally ill patients with gastrointestinal tumors
    Deniz Gencer
    III Medizinische Klinik, Universitatsmedizin Mannheim, Universitat Heidelberg, Mannheim, Germany
    Onkologie 32:380-6. 2009
    ..Few data have been published about terminally ill patients with gastrointestinal tumors treated in palliative care units...
  35. doi Down-regulation of MMP-2 expression due to inhibition of receptor tyrosine kinases by imatinib and carboplatin in HNSCC
    Johannes D Schultz
    Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Mannheim, Mannheim, Germany
    Oncol Rep 25:1145-51. 2011
    ..Further studies are warranted, especially one keeping in mind the moderate toxicity of imatinib...
  36. doi Cancer patients and the Internet: a survey of the 'Quality of Life' Working Groups of the Arbeitsgemeinschaft für Internistische Onkologie and the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie
    Deniz Gencer
    III Medizinische Klinik für Hämatologie und Onkologie, Universitatsmedizin Mannheim, Germany
    Onkologie 34:435-40. 2011
    ..Nevertheless, numerous obstacles exist regarding the implementation of QoL assessment in the daily practice of medical oncologists. Regular, computerized or internet home-based QoL assessments could be a step forward...